<DOC>
	<DOCNO>NCT00557856</DOCNO>
	<brief_summary>The purpose study test safety effectiveness PF-03446962 give single agent . Tumors require new blood vessel support ability grow spread ( metastasize ) . New treatment aim prevent blood vessel ability improve clinical management cancer .</brief_summary>
	<brief_title>A First In Patient , Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Advanced measurable nonmeasurable solid tumor Adequate bone marrow function Adequate liver function Adequate renal function Be able willing comply study schedule visit , treatment plan , laboratory test procedure Chemotherapy , radiotherapy , investigational cancer therapy within 4 week first dose study medication Active bleeding disorder , include gastrointestinal bleeding , evidence hematemesis , hemoptysis melena past 6 month Any follow within 12 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident include transient ischemic attack , pulmonary embolus ; active thromboembolic event QTc prolongation define QTc &gt; 450 msec Patients know brain metastasis Patients peritoneal carcinosis risk bleed Major surgical procedure within 4 week treatment Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Solid Tumors Transforming Growth Factor Beta Activin Receptor-like Kinase 1</keyword>
</DOC>